Platelets are key mediators in the pathophysiology of atherothrombotic disease.
Inappropriate platelet activation can lead to thrombosis and ischemic events. Platelet …

Opinion statement Dual antiplatelet therapy with a combination of aspirin and an inhibitor of
the ADP P2Y 12 receptor is the recommended treatment for patients with acute coronary …

Studies focused on patient responsiveness to antiplatelet therapies, particularly aspirin and
clopidogrel, have increased in recent years. However, the relations of in vivo platelet …

Platelets play a central role in the regulation of both thrombosis and haemostasis yet tests of
platelet function have, until recently, been exclusively used in the diagnosis and …

Oral antiplatelet therapy is routinely administered to ACS patients as well as to patients
undergoing percutaneous coronary intervention (PCI) with the primary aim of inhibiting …

Anti-platelet agents are a cornerstone in the treatment of symptomatic coronary artery
disease and acute coronary syndromes. Despite the proven benefits of acetylsalicylic acid …

In vitro platelet function tests are commonly applied in research and offer justification for
using antiplatelet therapy. However, studies assessing the ability of standardized platelet …

Platelet function testing was introduced more than a century ago with the invention of
bleeding time; a test which has now been replaced by more accurate methods. Light …

Guidelines provide a Class IA recommendation for the use of dual antiplatelet therapy in
patients undergoing percutaneous coronary intervention (PCI). However, there is …

O ver the past years there has been accumulating evidence on the prognostic value of
platelet function on cardiovascular outcomes (1). In particular, patients who persist with …